Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

Skin Cancer Surveillance and Malignancies of the Skin in a Community-Dwelling Cohort of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

(2014) Aaron S. Mansfield et al.   Journal of Oncology Practice

Suboptimal dosing of rituximab in male and female patients with DLBCL

(2013) M. Pfreundschuh et al.   BLOOD

Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study

(2013) S Beiggi et al.   BRITISH JOURNAL OF CANCER

Cancer risk with alemtuzumab following kidney transplantation

(2013) C. Puttarajappa et al.   CLINICAL TRANSPLANTATION

Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia

(2013) Paolo Strati et al.   LEUKEMIA & LYMPHOMA

Chronic Lymphocytic Leukemia Is Associated With Decreased Survival of Patients With Malignant Melanoma and Merkel Cell Carcinoma in a SEER Population-Based Study

(2012) Jerry D. Brewer et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma

(2012) Yuanlin Xu et al.   LEUKEMIA & LYMPHOMA

The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011)

(2012) Melhem Solh et al.   LEUKEMIA & LYMPHOMA

Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide

(2011) M. Čolović et al.   BIOMEDICINE & PHARMACOTHERAPY

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

(2011) S. A. Parikh et al.   BLOOD

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia

(2011) X. C. Badoux et al.   BLOOD

Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study

(2011) J A Royle et al.   BRITISH JOURNAL OF CANCER

Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis

(2011) Davide Rossi et al.   INTERNATIONAL JOURNAL OF CANCER

Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma

(2010) Corrado Tarella et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients

(2010) Pimjai Niparuck et al.   LEUKEMIA & LYMPHOMA

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

(2008) C. S. Tam et al.   BLOOD

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

(2008) Apostolia-Maria Tsimberidou et al.   JOURNAL OF CLINICAL ONCOLOGY